Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
284
resultados
Última actualización
11/05/2026 [08:29:00]
Resultados 25 a 50 de 284
Resumen de: US20260117174A1
An object of the present invention is to provide a production method and a culture method of a three-dimensional cell culture containing human-derived neurons, human-derived astrocytes, and human-derived microglia capable of mimicking human brain functions; a three-dimensional cell culture containing human-derived neurons, human-derived astrocytes, and human-derived microglia capable of mimicking human brain functions; and an evaluation method of a test substance using the three-dimensional cell culture. According to the present invention, there is provided a production method of a three-dimensional cell culture, the production method including a step of adding, prior to co-culture of cells, human-derived astrocytes, human-derived neurons, and human-derived microglia to a culture vessel, and a step of co-culturing the astrocytes, the neurons, and the microglia in the culture vessel, in which a proportion of the astrocytes among all cells added to the culture vessel is 30% or more.
Resumen de: WO2024088788A1
The present invention concerns the diagnosis and assessment of juvenile myelomonocytic leukemia (JMML). In particular, it relates to a method of diagnosing JMML in a subject, the method comprising a) determining the amount of at least one biomarker present on or in hematopoietic stem and progenitor cells (HSPCs) in a biological sample, said at least one biomarker being selected from each of i) group I consisting of: CD52, RAMP1, LTB, LST1, JAML, IFITM3, CD7, CD69, CD 164, CD74, TNF, TFPI, DLK1, CD82, IGHM, CALCRL, RALA, SLC2A5, HSPA5, HLA-DRA, RABI 1 A, SELL, VAMPS, FCMR, CLEC7A, NDFIP1, CLEC9A, HCST, LPAR6, HLA-DQA1, HLA-DRB5, and CD34, and ii) group II consisting of: IGLL1, BEST1, EREG, SLC5A3, SELK, PRRG3, NINJ1, MGST1, and HLA-G, b) comparing the determined amount of step a) to a reference, and c) diagnosing JMML based on the comparison of step b). Furthermore, the present invention relates to a method of classifying a subject suffering from JMML into a JMML low- or high-risk group. In addition, the present invention concerns use of at least one biomarker present on or in HSPCs in a biological sample for diagnosing JMML into a JMML low- or high-risk group in a subject having or having a risk of developing JMML. Furthermore, the present invention relates to a kit for diagnosing JMML in a subject or classifying a subject suffering from JMML into a JMML low- or high-risk group. Also, the present invention concerns an inhibitory agent that specifically inhibits at least one b
Resumen de: US20260115235A1
0000 It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
Resumen de: US20260118323A1
A method for determining multi-characteristic components of ASDZW is provided. By optimizing the gradient elution program of high performance liquid chromatography (HPLC), strictly controlling the initial mobile phase ratio of the gradient elution program, cooperating with the selections of the chromatographic column and the mobile phase, the invention finally realizes the simultaneous, rapid and comprehensive determination of six characteristic components in ASDZW under the condition of a single wavelength; specifically, the six characteristic components are polygalaxanthone III, 3,6′-disinapoyl sucrose, ginseng saponin Rb1, β-asarone, dehydrotumulosic acid, and pachymic acid. The whole detection process is a single wavelength detection with high detection efficiency and short analysis time, and the detection limits of the six components are lower than 0.008 μg/mL, meaning this method has high sensitivity, good specificity, accurate results, and good reproducibility.
Resumen de: US20260118346A1
Provided herein are methods of determining a cognitive status of a test subject. In some embodiments, the methods include passing a test subject data set through a model that relates test subject data sets to cognitive status of the test subjects in which the model was created using reference subject data sets produced by determining three or more features from samples obtained from the reference subjects using at least a thioflavin T (ThT) assay, a dynamic light scattering (DLS) assay, and a neurotoxicity assay. In some embodiments, the methods also include outputting from the model a classification of the test subject as having a Parkinson's disease (PD) status of PD-NC (normal cognition) or PD-CI (cognitive impairment). Related systems, computer readable media, and additional methods are also provided.
Resumen de: US20260118350A1
The present invention relates to novel compounds capable of localized fluorescent signal amplification by peroxidase, a method for preparing them, and their uses as fluorescent probes. The compounds according to the present invention serve as new fluorescent amplification probes utilizing peroxidase, enabling the generation of a localized labeling pattern at the target site. Through this, they provide super-resolution protein localization information and allow the visualization of interactions between various organelles. Furthermore, they can provide localized and stable fluorescent signals in CLEM and super-resolution imaging and enable selective fluorescent labeling under fixed conditions, making them highly applicable in future proteomics and live-cell imaging.
Resumen de: US20260118371A1
Disclosed herein are methods for diagnosing a subject as having a neurological disorder, such as Alzheimer's disease, using proximity-based detection assays capable of detecting complexes containing two or more synaptic proteins, such as neuronal pentraxins, from a blood, cerebrospinal fluid, or other fluid sample of the subject. Also disclosed are methods of evaluating and monitoring subjects having or at risk of developing a neurological disorder using the aforementioned assays.
Resumen de: US20260118363A1
An application of GluN2A and an NMDA receptor containing GluN2A as targets in screening antidepressant drugs, which may achieve rapid and low-cost screening of antidepressant drugs. Specifically, provided is a use of GluN2A, a binding fragment thereof or an NMDA receptor containing GluN2A in screening antidepressant drugs or in the preparation of a reagent for screening antidepressant drugs. Also provided are a method and apparatus for screening antidepressant drugs, and a kit.
Resumen de: EP4733313A2
0001 Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.
Resumen de: EP4733767A2
A method of detecting the presence of alpha-synuclein aggregation in a biological sample is provided whereby a biological sample is mixed with a reaction sample comprising a population of beads, a fluorophore adapted to bind to protein aggregates and to increase fluorescence when bound to protein aggregates, and alpha-synuclein or a fragment or variant thereof to form a reaction mixture, wherein a significant increase in the fluorescence of the reaction mixture during incubation is indicative of the presence of aggregates of alpha-synuclein in the biological sample.
Resumen de: EP4733761A1
0001 A simple and rapid method is provided for screening proteins associated with neurodegenerative diseases or compounds useful for the treatment or prevention of neurodegenerative diseases. The method uses a probe comprising a polypeptide comprising a dipeptide repeat sequence consisting of repeating units selected from the group consisting of proline-arginine, glycine-arginine, proline-alanine, glycine-alanine, and glycine-proline, and an environment-sensitive fluorophore covalently linked thereto.
Resumen de: WO2023159001A1
The disclosure relates to methods of diagnosis and prognosis, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non- T cells, TCR-based therapies, CAR-based therapies, bispecific T-cell engagers (BiTEs), and/or immune checkpoint blockade).
Resumen de: MX2022014319A
An expression vector is provided for production of human alpha-synuclein (αS) protein or a conservative variant thereof that exhibits a decreased tendency to self-aggregate in an αS seed amplification assay (SAA). The expression vector comprises a nucleic acid sequence coding for human αS protein or a conservative variant, the nucleic acid sequence comprising codons that have been optimized to produce human αS protein or a conservative variant when expressed by a host cell such as E. Coli. The codons have been optimized to avoid amino acid misincorporation in the expressed protein. Methods for purification of the expressed protein are also provided.
Resumen de: US20260110685A1
Disclosed herein are methods for analyzing quantitative expression values of biomarkers of a biomarker panel for determining disease activity in a human subject. Further disclosed herein are kits for measuring quantitative expression values of the markers as well as computer systems and software embodiments of predictive models for determining disease activity in human subjects based on the quantitative expression values of the markers.
Resumen de: WO2026084225A1
The present invention relates to a method for screening a lysophagy activator by promoting ubiquitination, and a pharmaceutical composition that contains the lysophagy activator selected by the screening method, and thus can treat or prevent lysosomal regulatory disorders, such as lysosomal storage disorders, neurodegenerative diseases, diabetes, or cancers.
Resumen de: WO2026085187A1
Described herein are multiplex single molecule assays for ultrasensitive detection of biomolecules, based on an ultrasensitive multiplex digital ELISA platform that substantially reduces cross-reactivity, and methods of use thereof.
Resumen de: WO2026084043A1
The present disclosure provides a technique relating to mild cognitive impairment detection using a skin blotting sample. In this disclosure, the mild cognitive impairment detection uses a mild cognitive impairment detection marker containing at least one selected from the group consisting of Aβ - (39 + 37 + 36)/ALB, Aβ - (39 + 37)/ALB, and Aβ - (37 + 36)/ALB as a detection index.
Resumen de: US20260110699A1
0000 A method for detection or monitoring status of traumatic brain injury (TBI) and/or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP/FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP/FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB/HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.
Resumen de: US20260110682A1
0000 Methods for identifying agents or manipulations that modulate copper (Cu) dyshomeostasis in an Mblac1- or swip-10-dependent manner, and for identifying agents that support Cu-dependent neuronal health in a subject are provided.
Resumen de: US20260110700A1
Provided are methods and kits for blood sample collection, protein extraction, and analysis of neuro biomarkers obtained from blood samples on dried blood drop cards.
Resumen de: US20260109946A1
The present invention provides methods and compositions for the generation of microglial progenitor cells and microglial cells from pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells. The present invention also provides cells produced using such methods, and both methods of treatment and methods of drug screening that use such cells. Also provided are various tissue culture media, tissue culture media supplements, and kits useful for the generation of human microglial progenitor cells and human microglial cells.
Resumen de: AU2024342922A1
The present disclosure provides cell penetrating agents comprising a cell internalization module and an antibody or antigen binding antibody fragment thereof that specifically binds to human beta amyloid and methods of using these cell penetrating agents to treat patients with beta amyloid related diseases, including Inclusion-body myositis (IBM).
Resumen de: WO2026084453A1
The present invention relates to a drug delivery system capable of efficiently penetrating the blood-brain barrier (BBB). More specifically, the present invention relates to a drug delivery platform which fuses transthyretin (TTR) or a functional variant thereof with a peptide sequence comprising a certain amino acid sequence, and thus can be applied to a therapeutic agent for brain diseases and a diagnostic composition.
Resumen de: WO2024200757A1
The present disclosure relates to methods of identifying and reducing anti-Fc epsilon Receptor I (FcεRI) immunoglobulins (Ig) associated with adverse reactions from plasma or a fraction thereof, formulations and uses of the anti-FcεRI Ig reduced plasma protein product thereof.
Nº publicación: US20260109740A1 23/04/2026
Solicitante:
WHITEHEAD INSTITUTE FOR BIOMEDICAL RES [US]
Resumen de: US20260109740A1
The disclosure provides, in various embodiments, polynucleotides comprising a polyamine-responsive element and a reporter protein coding sequence encoding a reporter protein, wherein interaction between a polyamine and the polyamine-responsive element modulates expression of the reporter protein. The disclosure also provides, in various embodiments, vectors cells, and kits comprising the polynucleotides, methods of reporting an intracellular polyamine, and methods of detecting and/or reporting an intracellular polyamine analog.
BOPI
Sede Electrónica
